Skip to content

Connecting business. Building understanding. Advancing peace.

Arcera Licenses Innogen’s GLP-1 Drug in Deal Valued Over $1 Billion

Abu Dhabi-based Arcera Life Sciences has entered an exclusive licensing agreement with China-based Innogen Pharmaceuticals to develop and commercialize the GLP-1 therapy efsubaglutide alfa. Arcera gains commercial rights across priority markets including the UAE, the Middle East, Africa, Eastern Europe, and Latin America. The transaction includes $15 million upfront, up to $38 million in near-term milestones, and future payments that could bring total deal value beyond $1 billion.

Illustration: A modern pharmaceutical laboratory interior with sterile stainless steel workstations, glass vials containing clear liquid, and scientif
Illustration

Abu Dhabi-based Arcera Life Sciences announced an exclusive licensing agreement with China-based Innogen Pharmaceuticals to develop and commercialize the GLP-1 therapy efsubaglutide alfa, according to Fierce Pharma.

Under the terms of the agreement, Arcera secures commercialization rights for the cardiometabolic medicine across designated international markets, including the United Arab Emirates, the wider Middle East, Africa, Eastern Europe, and Latin America.

Arcera will pay Innogen a non-refundable upfront fee of $15 million, along with up to $38 million in near-term milestones. In addition, Innogen is eligible to receive tiered double-digit royalties and future sales-based milestone payments.

The inclusion of royalties and sales milestones elevates the potential aggregate value of the transaction beyond $1 billion, providing the Abu Dhabi company access to scale an innovative treatment developed in China.

Sources

The UECN Brief

Policy updates, China–UAE business news and industry insights, delivered to your inbox.

Language
Subscriptions

Double opt-in: we send a confirmation link. Unsubscribe at any time. Privacy